Johnson & Johnson Surgical Vision, Inc.
Clinical trials sponsored by Johnson & Johnson Surgical Vision, Inc., explained in plain language.
A subsidiary of Johnson & Johnson focused on ophthalmic surgical devices and cataract surgery.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New cataract lens shows promise in early trial
Disease control Stopped earlyThis study tested a new type of artificial lens (TECNIS DEN00V) for people having cataract surgery. It compared the new lens to a standard lens in 243 adults with cataracts. The goal was to see if the new lens improves vision at arm's length (66 cm) while keeping good distance vi…
Sponsor: Johnson & Johnson Surgical Vision, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New Laser-Like eye surgery device falls short – trial stopped early
Disease control Stopped earlyThis study tested a device called the ELITA System to reduce or eliminate nearsightedness (myopia) and astigmatism. It involved 96 adults aged 22 and older who received a lenticule removal procedure in one or both eyes. The trial was terminated early, so the planned results on sa…
Sponsor: Johnson & Johnson Surgical Vision, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC